PerkinElmer Equips J&J Innovation JLABS’ Incubator

Mar 07, 2015

Lab solutions provider PerkinElmer Inc. announced its collaboration with Johnson & Johnson Innovation to equip its JLABS @South San Francisco (JLABS @SSF) life science incubator with instruments and lab services to address the research needs of resident startups. Janssen Labs (ostensibly JLABS) is the no-strings-attached incubator network that Johnson & Johnson says, is home to more than 70 life science companies. JLABS @SSF is the newest member of the J&J Innovation JLAB network which includes an established San Francisco location as well as facilities in San Diego, Boston and most recently Houston.

Companies seeking to avail themselves of the infrastructure and support apply and go through a selection process which evaluates their eligibility based on a specific set of criteria. Among them, companies must be working in areas of potential strategic interest to Johnson & Johnson and target an important unmet medical need. Johnson & Johnson explains companies are also reviewed for soundness of their management approach and startups across consumer, pharmaceutical, medical device and digital health sectors are of great interest to the program’s administrators. Interested companies can apply at the following website: www.jnjinnovation.com/jlabs.

For its part, PerkinElmer will provide on-site staff and training as well as scientific application support, a new offering to JLABS residents. The collaboration, says PerkinElmer, will enable JLABS @SSF residents to perform a variety of research and development activities using the company’s advanced imaging and detection solutions for a wide range of life sciences and environmental health applications. These include: sample preparation, protein characterization, screening new drugs, performing assays for drug discovery, mass spectrometry analysis, next-generation sequencing, identifying adulterants and contaminants, and forensics testing.

“It is critical that growing companies in the healthcare and scientific space have access to the most cutting-edge lab infrastructure, assets, application knowledge and support to help drive their research efforts," says Jim Corbett, President, Human Health, PerkinElmer. "We look forward to working together with Johnson & Johnson Innovation to identify and meet the research needs of entrepreneurs as they advance their science and make breakthrough discoveries."

This approach, says PerkinElmer, aligns with the JLABS model, which provides lab space, instrumentation and other resources, such as operational support, education and business services to emerging life science companies in the biotech, pharmaceutical, medical device, and digital health spaces. According to Johnson & Johnson, “JLABS provides the tools and resources needed to help life science startups thrive. Residents have access to turnkey, state-of-the-art infrastructure as well as year-round commercialization curriculum and networking events, onsite team for operations and business services, all with no-strings attached.”

Lastly, JLABS links regional entrepreneurs with the full breadth of Johnson & Johnson Innovation, including opportunities to discuss funding, access third-party services, attend educational events and meet with R&D experts from the company’s medical device and diagnostic technology, consumer healthcare product and Janssen pharmaceutical teams.

PerkinElmer's OneSource® Laboratory Services team of certified engineers and scientific staff will provide the on-site expertise to assist the companies with their scientific processes. These services, says Perkin Elmer, “help reduce lab complexities and increase efficiencies, include: information services, compliance services, scientific services, lab relocation services and asset services, including asset management for multivendor instrument service and repair.”

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments